Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma

被引：0
作者：
Koji Kato
Shinichi Makita
Hideki Goto
Junya Kanda
Nobuharu Fujii
Kazuyuki Shimada
Koichi Akashi
Koji Izutsu
Takanori Teshima
Natsuko Fukuda
Tokuhito Sumitani
Hiroyuki Sumi
Shinji Shimizu
Yasuyuki Kakurai
Kenji Yoshikawa
Kensei Tobinai
Noriko Usui
Kiyohiko Hatake
机构：
[1] Kyushu University Graduate School of Medical Sciences,Department of Medicine and Biosystemic Science
[2] National Cancer Center Hospital,Department of Hematology
[3] Hokkaido University Faculty of Medicine,Department of Hematology
[4] Kyoto University,Department of Hematology and Oncology, Graduate School of Medicine
[5] Okayama University Hospital,Department of Hematology and Oncology
[6] Nagoya University Graduate School of Medicine,Department of Hematology and Oncology
[7] Daiichi Sankyo Co.,Department of Clinical Oncology and Hematology
[8] Ltd,Department of Lymphoma/Hematology Center
[9] Geriatric Health Services Facility Rehabilitation Care Funabashi,undefined
[10] The Jikei University Daisan Hospital,undefined
[11] Mita Hospital,undefined
[12] International University of Health and Welfare,undefined
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Axicabtagene ciloleucel; CD19-specific chimeric antigen receptor; Japan; KTE-C19; Non-Hodgkin lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：213 / 223
页数：10
相关论文
共 53 条
[1]  
Chihara D(2014)Differences in incidence and trends of haematological malignancies in Japan and the United States Br J Haematol 164 536-545
[2]  
Ito H(2016)Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program 2016 366-378
[3]  
Matsuda T(2017)Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study Blood 130 1800-1808
[4]  
Coiffier B(2017)Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma Cancer Sci 108 1109-1118
[5]  
Sarkozy C(2017)Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma N Engl J Med 377 2531-2544
[6]  
Crump M(2019)Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma N Engl J Med 380 45-56
[7]  
Neelapu SS(2020)Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study Lancet 396 839-852
[8]  
Farooq U(2017)Phase 1 Results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma Mol Ther 25 285-295
[9]  
Makita S(2019)Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial Lancet Oncol 20 31-42
[10]  
Yoshimura K(2020)Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel) Blood 136 40-42
123456